Skip to main content
Equibles

GLENMARK · Glenmark Pharmaceuticals Limited · Financials

Use GLENMARK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GLENMARK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
2,655.45 INR -19.55 (-0.73%) At close · Nov 12
Rebalance outlook locked
Volume · Nov 12 16.64K Avg daily vol (3M) 24.53K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
169.83B +27.5%
FY2026 Revenue FY2018–FY2026
Net Income
1.01M -100%
FY2026 Net Income FY2018–FY2026
Operating Cash Flow
34.45B +516.3%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
INR 158.47B 169.83B 133.22B 118.13B 129.9B 123.05B 109.44B 106.41B 98.65B 91.03B
INR 6.56B 5.73B 4.86B 5.82B 6.11B 4.87B 4.44B 4.17B 3.26B 3.02B
INR 2.02B 2.09B 2.07B 5.16B 3.5B 2.98B 3.53B 3.77B 3.35B 2.86B
INR 19.03B 19.85B 13.99B 364.95M 8.68B 14.41B 13.82B 10.96B 13.01B 11.19B
INR 4.52B 6.23B 3.52B 18.67B 4.91B 4.48B 4.12B 3.2B 3.76B 3.15B
INR 8.86B 1.01M 10.47B -15.02B 0 9.42B 0 0 0 0
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 5.59B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.